| Literature DB >> 29515444 |
Liliya E Nikitina1,2, Sergei V Kiselev1, Valeriya A Startseva1, Andrei V Bodrov1, Zulfiya R Azizova1, Olga T Shipina3, Inna V Fedyunina1, Sergei V Boichuk1, Olga A Lodochnikova4, Vladimir V Klochkov2, Leisan F Galiullina2, Aliya V Khaliullina1,2.
Abstract
In this article we present the synthesis of enantiomerically pure sulfoxide and study the influence of this compound on hemostasis. Detailed NMR studies and molecular dynamics simulations using sodium dodecyl sulfate (SDS) membrane models indicated that the bicyclic fragment of sulfoxide was embedded into the SDS micelle whereas the -SO(CH2)2OH fragment remained on the surface of the micelle and was in contact with the solvent. We also found that the pro-coagulative activity of sulfoxide was due to its ability to inhibit platelet activation and inhibited the catalytic activity of phospholipid surface which was involved in formation of coagulation clotting factor complexes.Entities:
Keywords: coagulation activity; molecular mechanism of coagulation activity; platelets aggregation; sulfoxides; terpenes
Year: 2018 PMID: 29515444 PMCID: PMC5825891 DOI: 10.3389/fphar.2018.00116
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Scheme 1Synthesis of sulfoxide 2.
Scheme 2Synthesis of sulfoxide 2a.
Figure 1X-ray data of sulfoxide 2a.
1H NMR chemical shifts (δ, ppm) and spin-spin interaction constants (in parenthesis J, Hz) of the compound in D2O and D2O+SDS solutions at 293 K.
| CH-1 | 1.81 ov | 46.04 | 1.87 ov | 46.02 |
| CH-2 | 2.45 m | 34.72 | 2.48 m | 34.79 |
| CH2-3 | 1.54; 1.99 m | 20.27 | 1.52; 2.03 m, ov | 20.51 |
| CH2-4 | 1.76; 1.86 ov | 25.20 | 1.84; 1.90 ov | 25.63 |
| CH-5 | 1.81 ov | 40.51 | 1.83 ov | 40.60 |
| CH2-6 | 0.89; 2.27 m | 32.28 | 0.95; 2.30 m, ov | 32.49 |
| C-7 | – | 37.91 | – | 38.30 |
| CH3-8 | 1.07 s | 26.94 | 1.11 s | 27.20 |
| CH3-9 | 0.88 s | 22.34 | 0.93 s | 22.76 |
| CH2-10 | 2.88; 2.98 ov | 53.90 | 2.89; 2.95 ov | 54.21 |
| CH2-11 | 2.85; 2.95 ov | 59.52 | 2.86 ov | 59.84 |
| CH2-12 | 3.87 (9.0; 3.9) q | 54.59 | 3.90 ov | 54.81 |
s, singlet; q, quadruplet; br, broadened signal; m, multiplet; ov, overlapped signal.
Figure 22D 1H-1H COSY spectrum of the compound in D2O, T = 293 K. The numeration of the protons corresponds to the Figure 1.
Figure 42D 1H-13C HMBC spectrum of the compound in D2O, T = 293 K. The numeration of the protons corresponds to the Figure 1.
Figure 71H NMR spectra of the compound in D2O (A) and D2O+SDS (B) solutions, T = 293 K. SDS signals marked by superscript.
Figure 32D 1H-13C HSQC spectrum of the compound in D2O, T = 293 K. The numeration of the protons corresponds to the Figure 1.
Influence of sulfoxide 2a on aggregation of platelets and indicators of coagulation hemostasis in vitro in patients with IHD.
| Collagen, % | 50–75 | 72 ± 3 | 0 | 12 ± 6 | 8 ± 4 | 71 ± 3 | 72 ± 2 | 70 ± 3 | 68 ± 4 | 70 ± 2 |
| Arachidonic acid, % | 62–69 | 68 ± 2 | 0 | 7 ± 4 | 5 ± 2 | 10 ± 4 | 64 ± 2 | 70 ± 4 | 68 ± 2 | 62 ± 4 |
| Adrenalin, % | 60–71 | 67 ± 5 | 10 ± 2 | 5 ± 2 | 10 ± 2 | 68 ± 4 | 73 ± 2 | 66 ± 4 | 68 ± 2 | 72 ± 2 |
| ADP, % | 50–75 | 66 ± 4 | 55 ± 2 | 58 ± 3 | 68 ± 2 | 66 ± 3 | 68 ± 2 | 64 ± 4 | 66 ± 2 | 47 ± 3 |
| Ristomycin, % | 50–75 | 70 ± 3 | 68 ± 4 | 70 ± 2 | 66 ± 5 | 70 ± 2 | 68 ± 3 | 70 ± 2 | 68 ± 4 | 70 ± 2 |
n, number of studies;
p < 0.001, statistically significant differences of samples compared with control;
Acetylsalicylic acid.
Figure 5The results of the MTS-based assay of cytotoxicity of sulfoxide 2a in the concentration range from 18 to 2.25 mM. Control is presented by 1.5% solution of ethyl alcohol. Cytostatic compound of comparison is etoposide (1.25 mM, Calbiochem, USA).
Figure 6(A) Plasma obtained from healthy donors; (B) Plasma after addition of platelets sample; (C) Plasma after addition of platelets sample containing sulfoxide 2a.
Influence of platelet concentrate containing sulfoxide 2a on coagulation properties of plasma.
| APTT, s | 24–35 | 28.6 ± 1.2 | 22.5 ± 1.5 | 31.4 ± 2.7 | 30.6 ± 1.8 |
| Prothrombin time, s | 11–16 | 10.7 ± 0.8 | 8.9 ± 0.1 | 12.1 ± 0.81 | 11.9 ± 0.6 |
| V—Fibrin clot growth retardation rate, μm/min | 20–29 | 26.3 ± 2.2 | 39.4 ± 4.1 | 31.7 ± 2.1 | 20.0 ± 3.21 |
| Tlag—Fibrin clot retardation time, min | 0.6–1.5 | 1.4 ± 0.1 | 1.39 ± 0.07 | 1.2 ± 0.12 | 1.82 ± 0.08 |
| Vi—Fibrin clot growth initial rate, μm/min | 39–51 | 49.5 ± 1.8 | 54.3 ± 0.2 | 50.9 ± 0.8 | 45.8 ± 0.8 |
| Vst—Growth stationary rate, min−1 | 22–28 | 26.3 ± 2.2 | 39.4 ± 4.1 | 31.7 ± 2.1 | 20.0 ± 3.2 |
| CS—size, μm | 800–1,200 | 1154 ± 125 | 1443 ± 153 | 1132 ± 32.1 | 891 ± 53 |
| D—fibrin clot density, relative units | 15,000–32,000 | 24981 ± 243 | 30818 ± 967 | 2577 ± 228 | 26121 ± 467 |
| Tsp—clot formation time, min | absent | absent | 26.6 ± 0.3 | absent | absent |
n, number of studies;
p < 0.05, statistically significant differences of blood test results compared to control plasma;
p < 0.05, statistically significant differences of blood results compared to plasma after platelet concentrate addition.
Figure 82D NOESY NMR spectrum of the compound in D2O+SDS solution, T = 293 K. Intermolecular NOEs are shown in bars. Mixing time was 0.2 s.
Figure 9Results of molecular dynamics simulations of sulfoxide 2a in SDS micelles.